Presentation is loading. Please wait.

Presentation is loading. Please wait.

HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis  Marie Robin, Raphaël Porcher, Annalisa Ruggeri, Didier Blaise,

Published byErnő Biró Modified over 6 years ago

Similar presentations

Presentation on theme: "HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis  Marie Robin, Raphaël Porcher, Annalisa Ruggeri, Didier Blaise,"— Presentation transcript:

1 HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis 
Marie Robin, Raphaël Porcher, Annalisa Ruggeri, Didier Blaise, Christine Wolschke, Linda Koster, Emanuele Angelucci, Friedrich Stölzel, Victoria Potter, Ibrahim Yakoub-Agha, Yener Koc, Fabio Ciceri, Jürgen Finke, Hélène Labussière-Wallet, Maria Jesús Pascual Cascon, Mareike Verbeek, Alessandro Rambaldi, Jan J. Cornelissen, Patrice Chevallier, Rohini Radia, Arnon Nagler, Nathalie Fegueux, Eliane Gluckman, Theo de Witte, Nicolaus Kröger  Biology of Blood and Marrow Transplantation  Volume 25, Issue 1, Pages (January 2019) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure 1 Outcome of patients according to the type of donor: (A) OS, (B) PFS, (C) NRM, and (D) relapse incidences. Potential significance between haplo and MisUD or haplo and CB are given in Table 3. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © Terms and Conditions

Download ppt "HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis  Marie Robin, Raphaël Porcher, Annalisa Ruggeri, Didier Blaise,"

Similar presentations

Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse.

Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse.
Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A.

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A.
Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow.

Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow.
Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous.

Allogeneic Hematopoietic Cell Transplantation in Patients Age Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous.
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood.

Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood.
CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological.

CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological.
Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis  Marie Robin, Federica Giannotti, Eric Deconinck, Mohamad Mohty,

Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis  Marie Robin, Federica Giannotti, Eric Deconinck, Mohamad Mohty,
Annalisa Ruggeri, Mary Eapen, Andromachi Scaravadou, Mitchell S

Annalisa Ruggeri, Mary Eapen, Andromachi Scaravadou, Mitchell S
Unrelated Cord Blood Transplantation for Acute Leukemia Diagnosed in the First Year of Life: Outcomes and Risk Factor Analysis  Annalisa Ruggeri, Fernanda.

Unrelated Cord Blood Transplantation for Acute Leukemia Diagnosed in the First Year of Life: Outcomes and Risk Factor Analysis  Annalisa Ruggeri, Fernanda.
Upfront Allogeneic Stem Cell Transplantation after Reduced-Intensity/Nonmyeloablative Conditioning for Patients with Myelodysplastic Syndrome: A Study.

Upfront Allogeneic Stem Cell Transplantation after Reduced-Intensity/Nonmyeloablative Conditioning for Patients with Myelodysplastic Syndrome: A Study.
Changing Trends of Unrelated Umbilical Cord Blood Transplantation for Hematologic Diseases in Patients Older than Fifty Years: A Eurocord-Center for International.

Changing Trends of Unrelated Umbilical Cord Blood Transplantation for Hematologic Diseases in Patients Older than Fifty Years: A Eurocord-Center for International.
Long-Term Outcomes of Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Acute.

Long-Term Outcomes of Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Acute.
Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic.

Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic.
Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation  Nicolaus Kröger, Victoria Panagiota, Anita.

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation  Nicolaus Kröger, Victoria Panagiota, Anita.
Umbilical Cord Blood Cytomegalovirus Serostatus Does Not Have an Impact on Outcomes of Umbilical Cord Blood Transplantation for Acute Leukemia  Olga Nikolajeva,

Umbilical Cord Blood Cytomegalovirus Serostatus Does Not Have an Impact on Outcomes of Umbilical Cord Blood Transplantation for Acute Leukemia  Olga Nikolajeva,
Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic.

Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic.
Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to Myelodysplastic Syndrome or Leukemia from Severe Aplastic Anemia: A Report.

Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to Myelodysplastic Syndrome or Leukemia from Severe Aplastic Anemia: A Report.
Dynamic of Bone Marrow Fibrosis Regression Predicts Survival after Allogeneic Stem Cell Transplantation for Myelofibrosis  Nicolaus Kröger, Tatjana Zabelina,

Dynamic of Bone Marrow Fibrosis Regression Predicts Survival after Allogeneic Stem Cell Transplantation for Myelofibrosis  Nicolaus Kröger, Tatjana Zabelina,
Effect of HLA-Matching Recipients to Donor Noninherited Maternal Antigens on Outcomes after Mismatched Umbilical Cord Blood Transplantation for Hematologic.

Effect of HLA-Matching Recipients to Donor Noninherited Maternal Antigens on Outcomes after Mismatched Umbilical Cord Blood Transplantation for Hematologic.

Similar presentations

Ads by Google